Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Showing 1 to 15 of 19 results for axitinib

  1. Avelumab with axitinib for untreated advanced renal cell carcinoma (TA645)

    Evidence-based recommendations on avelumab (Bavencio) with axitinib (Inlyta) for untreated advanced renal cell carcinoma in adults.

    Technology appraisal guidance
    Published
    2 September 2020
    View recommendations

    Sections for TA645

  2. Pembrolizumab with axitinib for untreated advanced renal cell carcinoma (TA650)

    Evidence-based recommendations on pembrolizumab (Keytruda) with axitinib (Inlyta) for untreated advanced renal cell carcinoma in adults.

    Technology appraisal guidance
    Published
    30 September 2020
    View recommendations

    Sections for TA650

  3. Axitinib for treating advanced renal cell carcinoma after failure of prior systemic treatment (TA333)

    Evidence-based recommendations on axitinib (Inlyta) for previously treated advanced renal cell carcinoma in adults.

    Technology appraisal guidance
    Published
    25 February 2015
    View recommendations

    Sections for TA333

  4. Nivolumab for previously treated advanced renal cell carcinoma (TA417)

    Evidence-based recommendations on nivolumab (Opdivo) for previously treated advanced renal cell carcinoma in adults.

    Technology appraisal guidance
    Published
    23 November 2016
    View recommendations

    Sections for TA417

  5. Cabozantinib for previously treated advanced renal cell carcinoma (TA463)

    Evidence-based recommendations on cabozantinib (Cabometyx) for previously treated advance renal cell carcinoma in adults.

    Technology appraisal guidance
    Published
    9 August 2017
    View recommendations

    Sections for TA463

  6. Everolimus for advanced renal cell carcinoma after previous treatment (TA432)

    Evidence-based recommendations on everolimus (Afinitor) for advanced renal cell carcinoma after previous treatment.

    Technology appraisal guidance
    Published
    22 February 2017
    View recommendations

    Sections for TA432

  7. Lenvatinib with everolimus for previously treated advanced renal cell carcinoma (TA498)

    Evidence-based recommendations on lenvatinib (Kisplyx) with everolimus for previously treated advanced renal cell carcinoma in adults.

    Technology appraisal guidance
    Published
    24 January 2018
    View recommendations

    Sections for TA498

  8. Tivozanib for treating advanced renal cell carcinoma (TA512)

    Evidence-based recommendations on tivozanib (Fotivda) for treating advanced renal cell carcinoma in adults.

    Technology appraisal guidance
    Published
    21 March 2018
    View recommendations

    Sections for TA512

  9. Renal cell carcinoma Pathways Pilot [ID6186]

    In development [GID-TA11186] Expected publication date: TBC

    Technology appraisal guidance
    In development

  10. Belzutifan for treating tumours associated with von Hippel-Lindau disease [ID3932]

    In development [GID-TA10817] Expected publication date: TBC

    Technology appraisal guidance
    In development

  11. Cabozantinib with nivolumab for untreated advanced renal cell carcinoma (TA964)

    Evidence-based recommendations on cabozantinib (Cabometyx) with nivolumab (Opdivo) for untreated advanced renal cell carcinoma in adults.

    Technology appraisal guidance
    Published
    10 April 2024
    View recommendations

    Sections for TA964

  12. Managed access

    Managed access allows patients to access promising new treatments that would otherwise not be recommended because it is too uncertain whether the treatment is cost-effective.

  13. Axitinib, everolimus, sorafenib and sunitinib for treated advanced or metastatic renal cell carcinoma [ID897]

    Discontinued [GID-TAG526]

    Technology appraisal guidance
    Discontinued

  14. Past appeals and decisions

    TA333 Renal cell carcinoma, locally advanced and/or metastatic (2nd line) - axitinib [ID518] 10 June 2013 TA219 Renal cell carcinoma...

  15. NICE recommended that clinical data, including genotype and sustained virological response at 12 weeks, are collected for all people having treatment with simeprevir in the NHS.

    treatments. Source guidance details Comes from guidance Axitinib for treating advanced renal cell carcinoma after failure of prior...

    Research recommendation
    Published
    9 June 2015